Difference between revisions of "Mirtazapine-paroxetine"

From Psychiatrienet
Jump to: navigation, search
 
Line 2: Line 2:
 
| from = mirtazapine  
 
| from = mirtazapine  
 
| to = paroxetine  
 
| to = paroxetine  
| stop =  
+
| stop = {{StopSSRI,SNRI}}
{{stopMirtazapine}}
+
| start = {{StartAntidepressant}}
| start =  
+
| info =
{{startParoxetine}}
+
* Safe target dose paroxetine = 20 mg
 
 
 
}}
 
}}

Latest revision as of 17:05, 24 February 2023

Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine
paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine

Switch medication from mirtazapine to paroxetine.[1] [2]

Nietinrijdenbord.png Stop mirtazapine
  • Day 1: Decrease dose to 50%
  • Day 8: Stop
Eenrichtingbord.png Start paroxetine
  • Day 1: Start with 50% of the target dose
  • Day 8: Increase dose to 100% of the target dose
  • Day 9 and after: Gradually increase dose as necessary
Infobord.png More information
  • Safe target dose paroxetine = 20 mg
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.